The investigation of how increased OGT activity affects molecular processes in metabolic disorders, like IPAH, will open new avenues for vascular research in other pulmonary diseases, including COPD, Asthma, and IPF, which have been associated with widespread metabolic changes and vascular dysfunction [47,49]. This evidence concerns the gene OGT and asthma.